Prof Dr Markus Peck-Radosavljevic, MD, Division of Gastroenterology & Hepatology, Department of Internal Medicine III, Medical University of Vienna, Waehringer Guertel 18-20, A-1090 Vienna, Austria. Tel.: 00431404006589; fax: 00431404004735; e-mail: [email protected]

Read the full text

About

PDF

Tools

Share a link

Email
Wechat
Bluesky

Abstract

Eur J Clin Invest 2012; 42 (6): 599–606

Background A polymorphism near the IL28B gene has been shown to be associated with virologic response to antiviral treatment in HCV-infected patients. The predictive value of interferon-gamma inducible protein 10 (IP10) on treatment outcome has been described in HCV patients. Data on combining these predictors in HIV-HCV-coinfected patients are not available.

Methods Virologic parameters, IL28B single nucleotide polymorphisms (SNP) and pretreatment serum IP10 were determined in HIV-HCV-coinfected patients having completed antiviral therapy with pegylated interferon/ribavirin.

Results A total of 72 HIV-HCV-coinfected patients were included in the study; 68% had HCV genotype (GT)-1/4 and 32% had HCV GT-2/3 infections. Rapid virologic response (63% vs. 28%; P = 0·023) and sustained virologic response (SVR: 81% vs. 51%; P = 0·008) rates were significantly higher in C/C vs. non-C/C patients. Patients with low pretreatment IP10 levels (< 400 pg/mL) achieved significantly higher SVR rates than patients with high (> 400 pg/mL) IP10 levels (78% vs. 13%; P < 0·0001). C/C SNP and low IP10 levels were associated with higher SVR rates in both patients with GT-1/4 and GT-2/3. The C/C patients with low IP10 achieved SVR rates of 97% compared with SVR rates of 9% in non-C/C patients with high IP10.

Conclusion The IL28B SNP influences rapid viral response, relapse rates and SVR. The combination of IL28B and IP10 represents a predictive model of SVR in HIV-HCV coinfection.

References

1 Ghany MG, Strader DB, Thomas DL, Seeff LB. Diagnosis, management, and treatment of hepatitis C: an update. Hepatology 2009; 49: 1335–74.
10.1002/hep.22759
CAS PubMed Web of Science® Google Scholar
2 Chen TY, Ding EL, Seage Iii GR, Kim AY. Meta-analysis: increased mortality associated with hepatitis C in HIV-infected persons is unrelated to HIV disease progression. Clin Infect Dis 2009; 49: 1605–15.
10.1086/644771
PubMed Web of Science® Google Scholar
3 Reiberger T, Ferlitsch A, Sieghart W, Kreil A, Breitenecker F, Rieger A et al. HIV-HCV co-infected patients with low CD4+ cell nadirs are at risk for faster fibrosis progression and portal hypertension. J Viral Hepat 2010; 17: 400–9.
10.1111/j.1365-2893.2009.01197.x
CAS PubMed Web of Science® Google Scholar
4 Matthews GV, Dore GJ. HIV and hepatitis C coinfection. J Gastroenterol Hepatol 2008; 23: 1000–8.
10.1111/j.1440-1746.2008.05489.x
PubMed Web of Science® Google Scholar
5 Soriano V, Puoti M, Sulkowski M, Cargnel A, Benhamou Y, Peters M et al. Care of patients coinfected with HIV and hepatitis C virus: 2007 updated recommendations from the HCV-HIV International Panel. AIDS 2007; 21: 1073–89.
10.1097/QAD.0b013e3281084e4d
PubMed Web of Science® Google Scholar
6 Carrat F, Bani-Sadr F, Pol S, Rosenthal E, Lunel-Fabiani F, Benzekri A et al. Pegylated interferon alfa-2b vs standard interferon alfa-2b, plus ribavirin, for chronic hepatitis C in HIV-infected patients: a randomized controlled trial. JAMA 2004; 292: 2839–48.
10.1001/jama.292.23.2839
CAS PubMed Web of Science® Google Scholar
7 Torriani FJ, Rodriguez-Torres M, Rockstroh JK, Lissen E, Gonzalez-Garcia J, Lazzarin A et al. Peginterferon Alfa-2a plus ribavirin for chronic hepatitis C virus infection in HIV-infected patients. N Engl J Med 2004; 351: 438–50.
10.1056/NEJMoa040842
CAS PubMed Web of Science® Google Scholar
8 Soriano V, Maida I, Nunez M, Garcia-Samaniego J, Barreiro P, Martin-Carbonero L et al. Long-term follow-up of HIV-infected patients with chronic hepatitis C virus infection treated with interferon-based therapies. Antivir Ther 2004; 9: 987–92.
CAS PubMed Web of Science® Google Scholar
9 Reiberger T, Kosi L, Maresch J, Breitenecker F, Payer BA, Wrba F et al. Mitochondrial toxicity is associated with virological response in patients with HIV and hepatitis C virus coinfection treated with ribavirin and highly active antiretroviral therapy. J Infect Dis 2010; 202: 156–60.
10.1086/653214
CAS PubMed Web of Science® Google Scholar
10 Askarieh G, Alsio A, Pugnale P, Negro F, Ferrari C, Neumann AU et al. Systemic and intrahepatic interferon-gamma-inducible protein 10 kDa predicts the first-phase decline in hepatitis C virus RNA and overall viral response to therapy in chronic hepatitis C. Hepatology 2010; 51: 1523–30.
10.1002/hep.23509
CAS PubMed Web of Science® Google Scholar
11 Reiberger T, Aberle JH, Kundi M, Kohrgruber N, Rieger A, Gangl A et al. IP-10 correlates with hepatitis C viral load, hepatic inflammation and fibrosis and predicts hepatitis C virus relapse or non-response in HIV-HCV coinfection. Antivir Ther 2008; 13: 969–76.
CAS PubMed Web of Science® Google Scholar
12 Ge D, Fellay J, Thompson AJ, Simon JS, Shianna KV, Urban TJ et al. Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearance. Nature 2009; 461: 399–401.
10.1038/nature08309
CAS PubMed Web of Science® Google Scholar
13 Rauch A, Kutalik Z, Descombes P, Cai T, Di Iulio J, Mueller T et al. Genetic variation in IL28B is associated with chronic hepatitis C and treatment failure: a genome-wide association study. Gastroenterology 2010; 138: 1338–45.
10.1053/j.gastro.2009.12.056
CAS PubMed Web of Science® Google Scholar
14 Suppiah V, Moldovan M, Ahlenstiel G, Berg T, Weltman M, Abate ML et al. IL28B is associated with response to chronic hepatitis C interferon-alpha and ribavirin therapy. Nat Genet 2009; 41: 1100–4.
10.1038/ng.447
CAS PubMed Web of Science® Google Scholar
15 Tanaka Y, Nishida N, Sugiyama M, Kurosaki M, Matsuura K, Sakamoto N et al. Genome-wide association of IL28B with response to pegylated interferon-alpha and ribavirin therapy for chronic hepatitis C. Nat Genet 2009; 41: 1105–9.
10.1038/ng.449
CAS PubMed Web of Science® Google Scholar
16 Thomas DL, Thio CL, Martin MP, Qi Y, Ge D, O’Huigin C et al. Genetic variation in IL28B and spontaneous clearance of hepatitis C virus. Nature 2009; 461: 798–801.
10.1038/nature08463
CAS PubMed Web of Science® Google Scholar
17 Staettermayer AF, Stauber R, Hofer H, Rutter K, Beinhardt S, Scherzer TM et al. Impact of IL28B genotype on the early and sustained virologic response in treatment-naive patients with chronic hepatitis C. Clin Gastroenterol Hepatol 2011; 9: 344–50.
10.1016/j.cgh.2010.07.019
CAS PubMed Web of Science® Google Scholar
18 Rallon NI, Naggie S, Benito JM, Medrano J, Restrepo C, Goldstein D et al. Association of a single nucleotide polymorphism near the interleukin-28B gene with response to hepatitis C therapy in HIV/hepatitis C virus-coinfected patients. AIDS 2010; 24: F23–9.
10.1097/QAD.0b013e3283391d6d
CAS PubMed Web of Science® Google Scholar
19 Lagging M, Askarieh G, Negro F, Bibert S, Soderholm J, Westin J et al. Response prediction in chronic hepatitis C by assessment of IP-10 and IL28B-related single nucleotide polymorphisms. PLoS One 2011; 6: e17232.
10.1371/journal.pone.0017232
CAS PubMed Web of Science® Google Scholar
20 Fattovich G, Covolo L, Bibert S, Askarieh G, Lagging M, Clement S et al. IL28B polymorphisms, IP-10 and viral load predict virological response to therapy in chronic hepatitis C. Aliment Pharmacol Ther 2011; 33: 1162–72.
10.1111/j.1365-2036.2011.04635.x
CAS PubMed Web of Science® Google Scholar
21 Darling JM, Aerssens J, Fanning G, McHutchison JG, Goldstein DB, Thompson AJ et al. Quantitation of pretreatment serum interferon-gammainducible protein-10 improves the predictive value of an IL28B gene polymorphism for hepatitis C treatment response. Hepatology 2011; 53: 14–22.
10.1002/hep.24056
CAS PubMed Web of Science® Google Scholar
22 Beinhardt S, Aberle JH, Strasser M, Dulic-Lakovic E, Maieron A, Kreil A et al. Serum level of IP-10 increases predictive value of IL28B polymorphisms for spontaneous clearance of acute HCV infection. Gastroenterology 2011 [Epub ahead of print].
PubMed Web of Science® Google Scholar
23 Bedossa P, Poynard T. An algorithm for the grading of activity in chronic hepatitis C. The METAVIR Cooperative Study Group. Hepatology 1996; 24: 289–93.
10.1002/hep.510240201
CAS PubMed Web of Science® Google Scholar
24 Rockstroh JK, Bhagani S, Benhamou Y, Bruno R, Mauss S, Peters L et al. European AIDS Clinical Society (EACS) guidelines for the clinical management and treatment of chronic hepatitis B and C coinfection in HIV-infected adults. HIV Med 2008; 9: 82–8.
10.1111/j.1468-1293.2007.00535.x
CAS PubMed Web of Science® Google Scholar
25 Simera I, Moher D, Hoey J, Schulz KF, Altman DG. A catalogue of reporting guidelines for health research. Eur J Clin Invest 2010; 40: 35–53.
10.1111/j.1365-2362.2009.02234.x
CAS PubMed Web of Science® Google Scholar
26 Moghaddam A, Melum E, Reinton N, Ring-Larsen H, Verbaan H, Bjoro K et al. IL28B genetic variation and treatment response in patients with hepatitis C virus genotype 3 infection. Hepatology 2011; 53: 746–54.
10.1002/hep.24154
CAS PubMed Web of Science® Google Scholar
27 Sakamoto N, Nakagawa M, Tanaka Y, Sekine-Osajima Y, Ueyama M, Kurosaki M et al. Association of IL28B variants with response to pegylated-interferon alpha plus ribavirin combination therapy reveals intersubgenotypic differences between genotypes 2a and 2b. J Med Virol 2011; 83: 871–8.
10.1002/jmv.22038
CAS PubMed Web of Science® Google Scholar
28 Neukam K, Nattermann J, Rallon N, Rivero A, Caruz A, Macias J et al. Different distributions of hepatitis C virus genotypes among HIV-infected patients with acute and chronic hepatitis C according to interleukin-28B genotype. HIV Med 2011; 12: 487–93.
10.1111/j.1468-1293.2011.00912.x
CAS PubMed Web of Science® Google Scholar

Citing Literature

Volume42, Issue6

June 2012

Pages 599-606

IL28B and interferon-gamma inducible protein 10 for prediction of rapid virologic response and sustained virologic response in HIV-HCV-coinfected patients

Abstract

References

Citing Literature

References

Information

About Wiley Online Library

Help & Support

Opportunities

Connect with Wiley

IL28B and interferon-gamma inducible protein 10 for prediction of rapid virologic response and sustained virologic response in HIV-HCV-coinfected patients

Abstract

References

Citing Literature

References

Related

Information